
Sign up to save your podcasts
Or


Dr. Stephen Johnston is professor of breast cancer medicine and consultant medical oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London.
At the European Society for Medical Oncology Virtual Congress 2020, Dr. Johnston presented results from the monarchE trial. This study compared treating people diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence with either standard hormonal therapy after surgery or two years of Verzenio (chemical name: abemaciclib) in addition to standard hormonal therapy.
Listen to the podcast to hear Dr. Johnston explain:
By Breastcancer.org4.3
4242 ratings
Dr. Stephen Johnston is professor of breast cancer medicine and consultant medical oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London.
At the European Society for Medical Oncology Virtual Congress 2020, Dr. Johnston presented results from the monarchE trial. This study compared treating people diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence with either standard hormonal therapy after surgery or two years of Verzenio (chemical name: abemaciclib) in addition to standard hormonal therapy.
Listen to the podcast to hear Dr. Johnston explain:

21,967 Listeners

1,116 Listeners

2,034 Listeners

1,691 Listeners

2,636 Listeners

3,495 Listeners

9,290 Listeners

53 Listeners

4,488 Listeners

328 Listeners

388 Listeners

20,139 Listeners

1,171 Listeners

120 Listeners

30 Listeners